A PHASE III MULTICENTER RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
